SLC5A2 and heart failure: Empagliflozin and dapagliflozin, two members of sodium-glucose cotransporter 2 inhibitors (SGLT2i) which promote urinary glucose loss, profoundly reduce the risk of hospitalization for heart failure (HF) across broad range of patient characteristics1–3.